Invention Grant
US09073932B2 Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases
有权
取代的吡咯并[2,3-B]吡嗪用于治疗疾病和疾病
![Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases](/docs/US/2015-07-07/US09073932B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases
- Patent Title (中): 取代的吡咯并[2,3-B]吡嗪用于治疗疾病和疾病
-
Application No.: US14565571Application Date: 2014-12-10
-
Publication No.: US09073932B2Publication Date: 2015-07-07
- Inventor: Claire Adcock , Catherine Leblanc
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Shawn Britt
- Main IPC: C07D487/04
- IPC: C07D487/04
![Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases](/abs-image/US/2015/07/07/US09073932B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides compounds of formula (Ia) and (Ib) which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said compounds and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
Public/Granted literature
- US20150094312A1 SUBSTITUTED PYRROLO[2,3-B]PYRAZINE COMPOUNDS AND THEIR USE Public/Granted day:2015-04-02
Information query
